What is he best known for?
The fields of study he is best known for:
Rork Kuick mainly focuses on Gene expression profiling, Cancer research, Internal medicine, Pathology and Gene expression.
His research in Gene expression profiling intersects with topics in Cancer, Adenocarcinoma, Bioinformatics, Microarray analysis techniques and DNA microarray.
His Adenocarcinoma research includes elements of Immunohistochemistry, Clear cell, Microarray, Lung and Lung cancer.
His Cancer research research focuses on Tissue microarray and how it relates to Blot and Adrenal cortex.
His Internal medicine research includes themes of Endocrinology and Oncology.
His Gene expression study is concerned with Gene in general.
His most cited work include:
- Gene-expression profiles predict survival of patients with lung adenocarcinoma (1732 citations)
- p53-Mediated Activation of miRNA34 Candidate Tumor-Suppressor Genes (924 citations)
- Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. (849 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Cancer research, Molecular biology, Genetics, Gene and Gene expression.
His Cancer research research incorporates themes from Carcinogenesis, Cancer, Internal medicine, Endocrinology and In vivo.
His Cancer research incorporates elements of Bioinformatics and Pathology.
His study on Molecular biology also encompasses disciplines like
- Adenocarcinoma together with Lung and Lung cancer,
- Gene duplication that connect with fields like Amplicon.
His research in Gene expression is mostly concerned with Gene expression profiling.
Gene expression profiling is closely attributed to Microarray analysis techniques in his research.
He most often published in these fields:
- Cancer research (36.00%)
- Molecular biology (29.50%)
- Genetics (19.50%)
What were the highlights of his more recent work (between 2016-2020)?
- Cancer research (36.00%)
- In vivo (6.50%)
- Cancer (13.50%)
In recent papers he was focusing on the following fields of study:
Rork Kuick mostly deals with Cancer research, In vivo, Cancer, Carcinogenesis and Medulloblastoma.
His multidisciplinary approach integrates Cancer research and Context in his work.
In his study, Ovulation, Serous carcinoma, PTEN, OVGP1 and Epithelium is strongly linked to Serous fluid, which falls under the umbrella field of Cancer.
His Carcinogenesis research is multidisciplinary, incorporating perspectives in KRAS, Mutant protein, Allele, Null allele and Adenomatous polyposis coli.
The study incorporates disciplines such as Epithelial cell adhesion molecule, Western blot, Transfection and Adenocarcinoma in addition to Tumor Specific Peptide.
His Ligand study frequently involves adjacent topics like Molecular biology.
Between 2016 and 2020, his most popular works were:
- High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease. (43 citations)
- Granulocyte-derived TNFα promotes vascular and hematopoietic regeneration in the bone marrow (41 citations)
- BRAFV600E cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis (32 citations)
In his most recent research, the most cited papers focused on:
Rork Kuick focuses on Cancer research, Pathology, Peptide binding, Cancer and Epithelium.
Rork Kuick interconnects Missense mutation, Carcinogenesis, Mutant, Biopsy and KRAS in the investigation of issues within Cancer research.
His Pathology research integrates issues from Colonoscopy, Sessile serrated adenoma, Hyperplastic Polyp and PTEN.
His research in Peptide binding intersects with topics in Ex vivo, Biodistribution, In vivo and Breast cancer.
His biological study spans a wide range of topics, including Esophagus, Tissue biopsy, Dysplasia and Early detection.
Rork Kuick has included themes like Serous fluid, Oviduct, Serous carcinoma and OVGP1 in his Epithelium study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
